Comprehensive Cancer Panel

The Comprehensive Cancer Panel analyzes 109 genes associated with hereditary cancers across major organ systems, including: breast and gynecologic (breast, ovarian, uterine) gastrointestinal (colorectal, gastric, pancreatic) endocrine (thyroid, paraganglioma/pheochromocytoma, parathyroid, pituitary) genitourinary (renal/urinary tract, prostate) skin (melanoma, basal cell carcinoma) brain/nervous system sarcoma hematologic (myelodysplastic syndrome/leukemia) The Comprehensive Cancer Panel is designed to maximize diagnostic yield for individuals with a personal or family history of mixed cancers affecting multiple organ systems. Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. Heterozygous Pathogenic/Likely pathogenic germline variants in RAD50 and NBN are not clearly associated with an increased risk for cancer; however, such variants may qualify certain patients for clinical trials targeting homologous recombination deficient tumors. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.